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In the search for new anti-schistosomal agents, a series of fifteen ortho-nitrobenzyl derivatives was 
assayed in vitro against both the schistosomulum (somule) and adult forms of Schistosoma mansoni. 
Compounds 8 and 12 showed significant activity against somules at low micromolar concentrations, 
but none was active against adults. The SAR demonstrated that the compounds most active against the 
parasite were mutagenic to the human cell line RKO-AS45-1 only at concentrations 10- to 40-fold higher 
than the worm-killing dose. Given their electrophilicity, compounds were also screened as inhibitors of 
the S. mansoni cysteine protease (cathepsin B1) in vitro. Amides 5 and 15 exhibited a modest inhibition 
activity with values of 55.7 and 50.6 % at 100 µM, respectively. The nitrobenzyl compounds evaluated 
in this work can be regarded as hits in the search for more active and safe anti-schistosomal agents. 
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INTRODUCTION
Schistosomiasis is a neglected tropical disease 
caused by a flatworm of the genus Schistosoma. The 
major species involved are S. haematobium, which causes 
the urogenital form of the disease, and S. mansoni and S. 
japonicum, which are responsible for the intestinal disease 
(Colley et al., 2014). An estimated 240 million people 
worldwide are infected by Schistosoma parasites and more 
than 700 million live in endemic areas (WHO, 2016a). 
Praziquantel, a pyrazino-isoquinoline derivative 
(Figure 1), is registered as an essential medicine by the 
World Health Organization (WHO, 2016b) and is the first 
choice therapy for schistosomiasis. It is active against all 
schistosome species and is safe and inexpensive. However, 
concerns over the possible development of resistance to 
praziquantel due to its large-scale use, motivates the search 
of new anti-schistosomal agents (Wang, Wang, Liang, 
2012; Caffrey, 2015). 
Oxamniquine is a pro-drug that is activated by a 
Schistosoma sulfotransferase enzyme (Pica-Mattoccia et 
al., 2006). It is only clinically useful against S. mansoni 
infections (Caffrey, 2007; Axton, Garnett, 1976). The 
activated derivative is a nitro-aromatic compound that 
displays a good leaving group (sulfate) at the benzylic 
position. This product dissociates forming an electrophilic 
agent, which alkylates the parasite DNA (Abdul-Ghani et 
al., 2009) (Figure 2). 
FIGURE 1 – Chemical structure of praziquantel.
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Nitro-aromatic compounds, such as fexinidazole, 
benznidazole, and niclosamide, (Figure 3) are known 
for their pharmacological potential and our group has 
investigated the biological activities of a series of ortho-
nitrobenzyl derivatives that act as alkylating agents (Lopes 
et al., 2015; Lopes et al., 2011; Soares et al., 2010). 
Based on the need for new anti-schistosomal 
agents, we evaluated the schistosomicidal activity of 
nitro-aromatic compounds, analogs of “activated” 
oxamniquine, against S. mansoni in vitro. These 
compounds would be active per se ,  without the 
requirement for sulfotransferase activation, as proposed 
in Figure 4. Evidence suggests that oxamniquine-resistant 
schistosomes do not express the enzyme sulfotransferase 
and therefore cannot convert the oxamniquine into its 
active form (Valentim et al., 2013; Pica-Mattoccia et 
al., 2006). Therefore, compounds that are active per se 
could be an alternative in the treatment of oxamniquine-
resistant S. mansoni infections.
Based on their electrophilic characteristics, 
compounds were also assessed as possible inhibitors of 
S. mansoni cathepsin B1 (SmCB1), as this enzyme bears 
FIGURE 2 – Oxamniquine mechanism of action.
FIGURE 3 – Examples of nitro-aromatic drugs. 
FIGURE 4 – Mechanism of action proposed for the ortho-nitrobenzyl derivatives synthesized. 
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a nucleophilic cysteine residue in its active site (Jílková 
et al., 2011; Klinkert et al., 1989). SmCB1 is an abundant 
cysteine protease in the parasite (Caffrey et al., 1997; 
Caffrey, Ruppel, 1997), contributes to the digestion of 
hemoglobin in the schistosome gut (Caffrey et al., 2004; 
Sajid et al., 2003) and is an attractive drug target (Jílková 
et al., 2011; Abdulla et al., 2007). 
However, as these nitrobenzyl derivatives act by 
DNA alkylation, studies to assess their mutagenicity were 
performed for a better comprehension of the possible 
genotoxic effects of these compounds on human host 
cells.
MATERIAL AND METHODS
Synthesis
The synthesis and characterization of the compounds 
1-15 were previously described by us (Lopes et al., 2015). 
The compounds were synthesized in 1 to 3 steps from 
commercially available starting materials (p-toluic acid, 
4-(bromomethyl)benzoic acid or 4-(chloromethyl)benzoic 
acid) (Figure 5). 
In vitro screening of S. mansoni somules and 
adult worms
Maintenance of the S.  mansoni  l i fe  cycle, 
preparation of somules and adult worms, compound 
storage, and treatment of somules and adult worms were 
as described (Abdulla et al., 2009; Colley, Wikel, 1974; 
Duvall, DeWitt, 1967). Somules were cultured for four 
days in the presence of compounds at three concentrations, 
0.1, 1.0 and 10 µM. Adults (approximately 5 pairs) were 
cultured for two days in the presence of 5 µM compound. 
We employ simple descriptors to describe the observable 
effects of compounds on the parasite (changes in shape, 
motility and general appearance; Table I) (Rojo-Arreola 
et al., 2014; Abdulla et al., 2009). To convert these 
observations into a partially quantitative output in order 
to facilitate relative comparisons of compound effects, 
each descriptor is awarded a score of 1 up to a maximum 
score of 4 (Table I; Fonseca et al., 2015; Long et al., 
2016). Evidence of degeneracy or death was awarded 
the maximum score of 4. Death was adjudicated as the 
lack of parasite movement over a continuous 30 sec 
viewing period after tilting of the plate in order to agitate 
the parasite. For adults, damage to the tegument (outer 
surface) was awarded a score of 4 on the understanding 
that surface damage is lethal to the parasite in vivo 
(Andrews et al., 1983). 
Enzymatic assays against the cathepsin B1 of 
Schistosoma mansoni (SmCB1)
The recombinant SmCB1 was expressed and purified 
as previously described (Sajid et al., 2003). The enzyme 
activity was measured by monitoring the cleavage of a 
fluorogenic substrate, Z-Phe-Arg-aminomethylcoumarin 
(Z-FR-AMC), with 340/440 nm excitation/emission 
filters, in a microplate reader Synergy 2 (Biotek®) from 
the Center of Flow Cytometry and Fluorimetry at the 
Biochemistry and Immunology Department (UFMG). 
To determine the initial reaction rates, fluorescence was 
monitored at 25 °C, for 20 minutes at 12s intervals at 
340/440 nm excitation/emission, using BioTek’s Gen5™ 
Reader Control and Data Analysis Software. Assays were 
performed using 20 μM substrate and 8 nM SmCB1 in 
sodium acetate buffer 0.1 M, pH 5.5, containing 0.01% 
Triton X-100 and 4 mM β-mercaptoethanol. In all 
assays, a 1% DMSO negative control and a 100nM E-64 
positive control (E-64 is an inhibitor of cysteine proteases 
like SmCB1) were employed. Enzyme inhibition was 
calculated based on initial rates compared to the DMSO 
control. Compound stock solutions were prepared in 
DMSO. 1 μL of the 20 mM DMSO stock solution was 
added to each well, to a total volume of 200 μL in buffer 
assay, resulting in a final concentration of 100 μM of the 
compound and 1% DMSO in the assay. All compounds 
were soluble at the screening concentration and conditions. 
Compounds were screened with or without pre-incubation 
with the enzyme, for 10 min with the enzyme at room 
temperature. All assays were performed in at least two 
independent experiments, each in triplicate. 
Cytokinesis-Block Micronucleus (CBMN) Assay 
To assess the potential of the nitrobenzyl compounds 
4, 8 and 12 to induce chromosomal mutations in vitro, 
the cytokinesis–block micronucleus assay (CBMN) 
was performed in the RKO-AS45-1 (ATCC CRL-2577) 
human cell line. The procedures were carried out as 
described by Fenech (2007), with adaptations (Gontijo 
et al., 2015). Briefly, the cells were seeded in 24-well 
plates (2.5 x 105 cells/well) and maintained at 37 °C in a 
humid atmosphere with 5% CO2. After 24 hours, the cells 
were washed twice with PBS and the treatments were 
performed in culture medium without serum for three 
hours. Each treatment was performed in triplicate and 
three independent experiments for each compound were 
carried out in this study. Four different concentrations (5, 
10, 20 e 40 µM) of the compounds 4, 8 and 12, diluted 
in culture medium, were evaluated. The negative control 
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group was treated with culture medium without serum, 
and a positive control group was established by treatment 
with methyl methanesulphonate (MMS - 400 μM). 
After completing the treatments, cells were washed 
twice with PBS and fresh complete medium containing 
cytochalasin-B (3.0 µg/mL) was added for 24 h. Next, 
the cells were processed, fixed and the slides were stained 
with DAPI (4’,6-diamidino-2-phenylindole – 1 µg/mL) 
diluted in PBS. The microscopic analysis was performed 
with a fluorescent microscope (Zeiss, Axioscope A1) 
FIGURE 5 – Synthesized nitro-aromatic compounds and non-nitrate analogs and general synthesis scheme. Reagents and conditions: 
(i) fuming HNO3, 0 ºC, 51-87%; (ii) EDC, NHS, dichloromethane, rt or 0 ºC, then corresponding amines, 22-74%; (iii) NaHCO3 (aq), 
80 ºC, 86%; (iv) tetrahydroisoquinoline (56%) or morpholine (64%), acetone, rt,; (v) butyric acid, EDC, DMAP, acetone, rt, 87%.
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with an excitation filter of 365 nm and a barrier filter of 
445/450 nm. One thousand binucleated cells with a well-
preserved cytoplasm were analyzed for each treatment in 
a blind test. Cells containing 1–3 micronuclei were scored 
(Gomes et al., 2011). The criterion for the identification 
of micronuclei (MNs) was according to a previous report 
(Titenko-Holland et al., 1997). For statistical analysis, 
ANOVA was performed followed by the Tukey post-test 
with a significance level of 0.05. 
Nuclear Division Index (NDI)
The influence of the synthetic compounds on cell 
proliferation was assessed by calculating the nuclear 
division index (NDI) in RKO-AS45-1. The same slides 
prepared for the CBMN assay were used, and 300 cells 
with a well-preserved cytoplasm were counted using 
fluorescence microscopy, as described above. The NDI 
was calculated according to Fenech (2007) and Eastmond 
and Tucker (1989), using the equation:
where M1–M4 are the numbers of cells with 1, 2, 3 and 4 
nuclei, respectively, and N is the total number of counted 
cells. For statistical analysis, ANOVA was performed 
followed by the Tukey post-test with a significance level 
of 0.05.
RESULTS AND DISCUSSION
Compounds 1-15 were synthesized according to 
previously reported procedures (Lopes et al., 2015) based 
on variations at the R1, R2 and R3 positions of sulfate-
oxamniquine (Figure 5). We tested the effect of different 
substituents at the benzylic (-R3) position because it 
is expected that the mechanism of action is by DNA 
alkylation. Analogues without the nitro group (13, 14 and 
15) were also assessed in order to evaluate the importance 
of this group for schistosomicidal activity. 
C o m p o u n d s  w e r e  s c r e e n e d  f o r  i n  v i t ro 
schistosomicidal activity against somules and adult 
S. mansoni as described above. The data for active 
compounds are presented in Table I. 
Three compounds (4, 8 and 12) elicited progressive 
and deleterious phenotypic alterations in S. mansoni 
somules: compounds 8 and 12 were the most potent. Both 
compounds caused degeneration of the parasites within 24 
h at 10 and 1 µM. These changes were eventually lethal. 
Effects (darkening of the parasite) were also noted at 
0.1 µM on the third day. As a comparator, oxamniquine 
induced less pronounced degenerative changes within 24 
h at 10 and 1 µM. Effects (slowing and darkening of the 
parasite) were also noted at 0.1 µM on the third day.
Taking into account that the mode of action of 
these compounds is by alkylation, it would be expected 
that compounds bearing a good leaving group, such as 
bromine and chlorine, to be the most potent. However, 
all compounds containing a bromine substituent were 
inactive. This can be explained by the lower stability of 
the bromo benzyl group in the assay medium. Thus, our 
results indicate that the chlorine leaving group shows 
the best apparent trade-off between activity and stability. 
As expected, compounds without a leaving group at the 
benzylic position (3, 6, 9, 10 and 11) showed no activity.
In contrast to the result obtained for compound 4, 
the corresponding non-nitrated analog 14 did not display 
TABLE I – Descriptorsa and severity scoresb for the responses of S. mansoni somules and adults to nitrobenzyl compounds 4, 8 and 12
Somule responses (and severity scores) on the indicated day Adult S. 
mansoni 
responses (and 
severity scores) 
at 5 µM on the 
indicated day
0.1 µM 1.0 µM 10.0 µM
1 2 3 4 1 2 3 4 1 2 3 4 1 2
4 ne (0) ne (0) ne (0) ne (0) ne (0) ne (0) ne (0) ne (0) ne (0) deg (4) D (4) D (4) ne (0) ne (0)
8 ne (0) ne (0) dk (1) dk (1) R, dk (2) R, dk (2) deg (4) deg (4) deg (4) D (4) D (4) D (4) ne (0) ne (0)
12 ne (0) ne (0) dk (1) dk (1) R, dk (2) deg (4) D (4) D (4) deg (4) D (4) D (4) D (4) ne (0) ne (0)
Oxa ne (0) ne (0) S, dk (2) n.t. R (1) dk (1) R, deg (4) n.t. R (1) dk (1) R, deg (4) n.t. ne  (0) S, dk (2) 
aDescriptors: ne = no effect, dk = dark, R = shape altered, deg = degenerating, D = death, S = slow, n.t. = not tested. bEach descriptor is awarded a 
‘severity score’ of 1 (in parentheses) and these are added up to the maximum score of 4. The descriptors ‘deg’ and ‘D’ are automatically awarded 
a score of 4. Oxa = oxamniquine.
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activity, suggesting a positive influence of nitro group 
on reactivity and activity. The electron-withdrawing 
character of this group may be associated with an increased 
electrophilicity of the benzylic carbon thereby promoting 
alkylation. 
Regarding the substituent at R1, compounds having 
a carboxylic acid group showed no activity against S. 
mansoni somules whereas amides containing a hydrogen 
bond acceptor atom in the side chain showed relevant 
activity. The morpholine-amide 8 was more potent 
than ethanolamide (4) and propylamide (7) analogs. 
Esterification of the hydroxyl group of 4 with butyric acid 
resulted in significant increase of activity.
These findings are in agreement with our previous 
studies (Lopes et al., 2015) which have indicated the 
importance of the presence of a good leaving group at the 
benzylic position for the antiproliferative activity these 
compounds on different human cancer cell lines (IC50 
ranging from 1.3 to 83.4 µM). However, unlike the results 
presented here, compounds bearing a benzyl bromide were 
cytotoxic for cancer cells independent of the presence of 
the nitro group.
In summary, the results found in the present study 
indicate that: a) the presence of a leaving group at the 
benzylic position is essential for the antishistosomal 
activity; b) the presence of a nitro group is also 
indispensable for the activity; c) compounds containing 
an amide group are more active than those containing a 
carboxylic acid group; d) compounds bearing a hydrogen 
bond acceptor atom in the side chain display higher 
activity. These assumptions are illustrated in Figure 6. 
Despite the results obtained in the somule assay, none 
of the compounds showed activity against the adult worm. 
In contrast, oxamniquine induced degenerative changes 
in adults on the second day of the incubation (Table I). 
The lack of activity may be due to an inability of the 
compounds to cross the adult parasite tegument (surface) 
and/or differences in expression of potential targets. 
Structural differences in the outer membrane of larval 
and adult stages are known (Hockley, McLaren, 1973). 
Also, differences in transcriptome expression profiles 
between developmental stages of the parasite, including 
between somules and adults are well documented (Liu 
et al., 2014; Liu et al., 2006; Verjovski-Almeida et al., 
2003). Modifications of the physicochemical properties of 
compounds could be performed in an attempt to enhance 
their membrane permeability.
Alkylating agents are potentially carcinogenic 
compounds that can introduce lesions at DNA nucleophilic 
centers (Sobol et al., 2007) and can cause clastogenic 
effects and, consequently micronuclei formation. 
Micronuclei are small, extranuclear chromatin bodies 
surrounded by a nuclear envelope, which arise in dividing 
cells from acentric chromosome fragments or whole 
chromosomes. They result in chromosomal alterations that 
have been transmitted to daughter cells and are frequently 
used as an endpoint in genotoxicity testing (Hintzchea et 
al., 2017). OECD guidelines (OECD, 2016) suggest the 
use of the micronucleus assay to assess the risks associated 
with potential clastogenic/aneugenic compounds and 
the FDA recommends the micronucleus assay in the test 
battery for genotoxicity testing of Pharmaceuticals (FDA, 
2016). 
As compounds 4, 8 and 12 are active per se it was 
necessary to evaluate their genotoxicity on a mammalian 
cell line. The CBMN assay was carried out using the 
human cell line RKO-AS45-1 (ATCC CRL-2577) and 
results are shown in Figure 7. Compound 4 was mutagenic 
only in the highest concentration assessed (40 µM) and 
the NDI was not altered in any concentration assessed. 
Compound 8 also induced chromosomal mutations on 
human cell line at 40 µM but the NDI was altered at 20 
and 40 µM, indicating a reduction in proliferation rate at 
these conditions. Compound 12 was able to induce DNA 
damages in concentrations ranging 10-40 µM but the NDI 
was reduced only at 20 and 40 µM.
These results showed that the ortho-nitrobenzyl 
halides really have a mutagenic effect, probably due to 
their alkylating potential. However, the concentrations 
needed to induce genotoxic effects in the human cell line 
used was much higher than those necessary to induced 
phenotypic alterations and death in S. mansoni (Table II). 
Furthermore, the alterations of the NDI observed to the 
compounds 8 and 12 showed that the human cells used 
responded to the damages induced by the compounds, 
probably arresting the cell cycle to promote the DNA 
repair. Unlike these compounds, studies indicate that 
FIGURE 6 – Key functional groups important for anti-
schistosomal activity.
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the oxamniquine has low mutagenic potential (Ray et al. 
1975), although there are reports of its mutagenic effect 
when tested on Salmonella typhimurium strain TA100 
(Batzinger, Bueding, 1977; Dayan, Deguingand, Truzman, 
1985).
Given the electrophilic nature of these derivatives 
and the nucleophilic character of catalytic cysteine 
in the protease SmCB1, these compounds were also 
evaluated against this enzyme, a pharmacological target 
for schistosomiasis (Jíková et al., 2011; Caffrey et al., 
1997). In order to evaluate their ability to inhibit SmCB1, 
FIGURE 7 - Mean and standard deviation of the frequency of micronuclei in binucleated cells and nuclear division index (NDI) 
after the treatment of RKO-AS45-1 human cell line with the compounds 4, 8 and 12 (incubation time = 3 hours). Three independent 
experiments were performed to each compound. *p<0.05 and **p<0.01 when compared with the control. MMS = Methyl 
methanesulfonate (400 µM).
TABLE II – In vitro effect of 4, 8 and 12 against S. mansoni 
somules and the least concentration necessary to induce 
genotoxicity
Compound Schistosomicidal activity (µM)*
Mutagenic 
Concentration (µM)
4 10.0 40.0
8 1.0 40.0
12 1.0 10.0
*Concentration of compound at which the maximum severity 
score of 4 is achieved.
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compounds 1-15 were screened in vitro at 100 µM with 
and without a pre-incubation period with the enzyme prior 
to addition of substrate (Table III). Most compounds were 
weak inhibitors of SmCB1 and appear to be slightly more 
effective when pre-incubated with the enzyme. Although 
o-nitrobenzyl derivatives present an electrophilic character 
and can potentially bind covalently to the cysteine residue, 
in order to do so they need to have sufficient affinity 
for enzyme active site. Thus, it is supposed that these 
compounds are not able to inhibit SmCB1 due to their 
poor complementarity to the enzyme’s active site. Amides 
5 and 15 showed the best results, with moderate inhibitory 
activity (55 and 50% respectively) with pre-incubation. 
These compounds have in common the ethanolamine 
chain and the bromine atom at the benzylic position. 
Further SAR studies are necessary to obtain compounds 
with more affinity and activity against SmCB1.
CONCLUSION
In conclusion, the ortho-nitrobenzyl derivatives 
8 and 12 showed significant activity against somules in 
vitro. A structure-activity relationship could be established 
with the identification of key functional groups of these 
alkylating agents. However, it was interesting to observe 
that they triggered the death of S. mansoni somules at 
lower concentrations than those that induced chromosomal 
mutations in human cells in vitro. Nevertheless, none of 
the compounds was active against the adult parasite in 
vitro and further modifications are needed to find analogs 
that display activity against both life stages of S. mansoni. 
None of the compounds efficiently inhibited SmCB1 in 
vitro.
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